Abstract: It relates to a lurasidone solid dispersion and a preparation method, wherein the method comprises melting treatment of a mixture containing lurasidone, a medicinal hot melt carrier, optionally an acidic regulator and plasticizer in order to obtain the solid dispersion described herein, and wherein the lurasidone is provided in a form of free base. The lurasidone solid dispersion obtained by the preparation method according to the example of the invention has the characteristics of high dissolution rate (dissolution rate can reach 30%-70%) in a partial neutral medium (e.g. pH6.0). The bioavailability of lurasidone solid dispersion increased significantly and the food effect of lurasidone solid dispersion prepared from the example decreased remarkably.

Abstract: The technology relates to a prophylactic bandage contact lens that prevents microbial infections in an eye as well as treats infection by dispensing antimicrobial medication at controlled rates. In one embodiment, the invention provides a bandage with nanostructures, and provides a continuous treatment over 10 days and shields the eye from the environment, significantly diminishing the risk of infection while allowing damaged tissues to heal.

Abstract: The present invention relates to controlled release pharmaceutical compositions comprising fumaric acid ester(s) as active substance(s). The compositions are suitable for use in the treatment of e.g. psoriasis or other hyperproliferative, inflammatory or autoimmune disorders and are designated to release the fumaric acid ester in a controlled manner so that local high concentrations of the active substance within the gastrointestinal tract upon oral administration can be avoided and, thereby, enabling a reduction in gastro-intestinal related side-effects.

Abstract: The invention relates to an oral formulation for targeted delivery of cholestyramine to the colon, comprising a plurality of cholestyramine pellets that are coated with a colon release coating. The invention also relates to the use of this formulation in the treatment of bile acid malabsorption.

Abstract: The present disclosure relates to methods, compositions, and kits for treating hair. The methods entail the use of multiple compositions, which can be incorporated into kits. The methods include: (I) optionally, cleansing the hair, for example, with a cleansing composition such as a shampoo; (II) optionally, treating the hair with a rinse-off conditioning mask, and rinsing the rinse-off conditioning mask from the hair; (III) applying a leave-on hair-treatment composition to the hair; (IV) without removing the leave-on hair-treatment composition, subsequently applying a leave-on hair crème to the hair; and (V) without removing the leave-on hair-treatment composition and the leave-on hair crème, styling the hair. The methods provide durable styling and conditioning benefits, frizz control/curl definition, and general hair manageability qualities.

Abstract: An improved medical implant device directed to, inter alia, (i) avoiding unwanted initial drug “burst” problems, (ii) providing a more level amount of drug delivery, (iii) reducing blood clotting, (iv) reducing the amount of drug material that remains in the implant device, and/or (v) novel materials for an implant device.

Abstract: The present invention relates to a formulation comprising a pharmaceutically active ingredient and a coating. The invention also relates to the use of the formulation in the treatment and prevention of disorders of the gastrointestinal tract. Also disclosed are methods for preparing the formulations.

Abstract: The present invention provides compositions comprising water soluble peptides with poor solubility in isotonic solutions which exhibit enhanced bioavailability with reduced adverse effects including injection site reactions. Methods are also disclosed for using such compositions for the treatment of diseases including, but not limited to, cancer, type 2 diabetes, acromegaly, metabolic disorders, endocrine disorders, exocrine tumors, and hormone-related tumors. Methods to reduce adverse injection site reactions and improve bioavailability are also disclosed.

Abstract: The present invention relates to a organopolysiloxane graft polymer including an organopolysiloxane segment as a main chain thereof and an unsaturated monomer-derived polymer segment as a side chain thereof, in which the unsaturated monomer-derived polymer segment contains a repeating unit derived from N,N-dimethyl acrylamide in an amount of not less than 50% by mass and not more than 100% by mass, and a content of the organopolysiloxane segment in the organopolysiloxane graft polymer is not less than 10% by mass and not more than 70% by mass.

Abstract: The present invention relates to an information medium to be handled by a large number of users, such as a banknote, and having antiviral properties, and to a method for making same.

Abstract: An edaravone suspension for human oral administration includes edaravone particles, a dispersant, and water.

Abstract: A wound care bandage for treating a wound is provided. The bandage includes an SIS layer to be placed on the wound surface and a cover to be placed over the wound. The bandage further includes a structure to provide a vacuum space. A method for promoting wound healing is further provided. The method includes applying the above-mentioned wound care bandage to the wound and creating a vacuum in the vacuum space to draw blood controllably from the wound into the SIS layer.

Abstract: The present invention relates to a composition comprising pharmaceutical active ingredients which are susceptible to, or have potential for, abuse. The invention provides an oral pharmaceutical composition comprising a first population of beads and a second population of beads. The first bead population comprises a pharmaceutically active ingredient susceptible to, or having the potential for, abuse. The second bead population comprises a gelling agent and a coating substantially surrounding the gelling agent, but containing no pharmaceutically active ingredient. The first bead population and the second bead population are physically separable, but visually indistinguishable to the naked eye. Upon ingress of water into the second population of beads, the gelling agent is caused to swell forming a viscous mass inhibiting or preventing the extraction of the active ingredient.

Abstract: The present invention relates to high drug load pharmaceutical compositions comprising Eslicarbazepine or its pharmaceutically acceptable salts, esters, solvates, polymorphs, enantiomers or mixtures thereof. The present invention also relates to a process for preparing high drug load solid oral pharmaceutical composition comprising Eslicarbazepine acetate and at least one pharmaceutically acceptable excipient. The prior art highlights various technical challenges for formulation development of Eslicarbazepine acetate at lab as well as at industrial scale and offer restrictive and complex approach for resolution of technical challenges. Compositions of Eslicarbazepine acetate prepared as per present invention, wherein disintegrant and/or binder is present in either intra-granular part or in extra-granular part of the composition exhibited desirable technical attributes like comparable dissolution and bioequivalence against reference listed drug.

Abstract: The present invention relates to an anhydrous colored cosmetic powder comprising at least one natural or synthetic silicate and at least one dye. During its preparation, such a powder may have contacted an aqueous phase which has subsequently been dried and is not present in its final state. The present invention also relates to a cosmetic composition comprising an aqueous phase and a non-aqueous phase comprising at least one colored powder portion, where the colored powder portion comprises at least one natural or synthetic silicate and at least one dye.

Abstract: The invention provides compositions, methods and kits for the removal of harmful or irritating substances from bodily surfaces. Kits may include a composition containing capsaicin and a capsaicin-cleansing composition, e.g., a composition in which capsaicin is soluble.

Abstract: A dosage delivery film composition containing a botanical drug substance formable into a bioerodible dosage delivery film, the dosage delivery film composition including: (i) one or more of: a polymer, a plasticizer, a defoamer, or an antioxidant; (ii) a cannabinoid-cyclodextrin-terpene complex or a cannabinoid-terpene-surfactant micelle, and (iii) optionally, one or more of: a taste mask, a vasodilator, or a lipophilic vehicle to transport the botanical drug substance across the mucous membrane.

Abstract: Lipid microcapsules are described that can include at least one lipophilic active substance, more specifically a retinoid, in a soluble form. Also described, are pharmaceutical compositions including the same and a method for the production thereof. Methods of using such a composition to treat dermatological pathologies are also described.

Abstract: A pharmaceutical or nutraceutical composition with a core, an inner coating layer, and an outercoating layer, wherein a pharmaceutical or a nutraceutical active ingredient is contained in the core, one or more salts of alginic acid is contained in the inner coating layer, and one or more water-insoluble polymers or copolymers is contained in the outer coating layer. In the composition, the ratio of the amount of the one or more salts of alginic acid in the inner coating layer is at least 2.5:1 by weight to the amount of the one or more water-insoluble polymers or copolymers in the outer coating layer.

Abstract: The instant disclosure relates to hair-treatment compositions. The hair-treatment compositions typically include: one or more polyurethane latex polymers; one or more thickening agents; one or more water-soluble solvents; and water. Additional components such as silicones, emulsifiers, surfactants, cationic polymers, etc., can also be included. The instant disclosure also relates to kits that include the hair-treatment compositions and to methods for treating hair with the hair-treatment compositions.